|
New Heart Research Poised to Help Millions
Biosignetics Announces Results of its Heart Sound Research.
Cardiac diseases, including heart attack and angina, are the leading causes of death in the developed countries. The American Heart Association estimates that about 12 million Americans have some kind of coronary heart disease, an estimated 2-4% of Americans suffer from heart diseases and further 10-12% are projected to be at risk. Studies published in American Medical Association Journal consistently show that most new doctors can't use stethoscope. According to Dr. Salvatore Mangione's study residents were wrong four out of five times, when asked to detect 12 different heart problems by listening with a stethoscope.
The very nature of heart attacks and the severity of their impact lead to high fatality rates with more than 60% of deaths occur before the victims reach the hospital. Once victims arrive to the hospital and survive the first day, overall chances of survival are significantly improved. This shows very clearly, that the earlier a heart disease is detected, the more likely it is to be cured or successfully managed.
Biosignetics Corporation has developed and applied state-of-the art signal processing computational algorithms aiming to aid physicians and medical students to enable early heart disease diagnosis during the routine medical checkups. New heart sound processing research leads to the invention of the Heart Energy Signature (http://www.bsignetics.com/serv02.htm ). It is based on inexpensive technology and allows mapping heart sound morphology in the same way X-rays or Ultrasound allows to get additional insight into a human body. Scientists developed a look up album of unique energy signatures that correspond with various heart conditions.
Present research brings many new possibilities in the sound based characterization of auscultatory documented human heart conditions (stenosis, regurgitation, splits, clicks, gallops, snaps, rumble, valve prolapse, murmurs, septal defect, patent ductus arteriosus, atrial septal defect). Resulting heart sound images are self-referencing and can be easily understood by the physicians, medical researchers and patients alike. Patent pending Heart Energy Signature has a great potential to become de-facto standard to record, store, compare and track sound based heart diagnosis data. It can be especially effective in heart disease related research and in educating medical students and doctors to perform auscultation more effectively.
Preliminary results also show an immense promise for use in neuroscience and for analysis of cortical brain responses, for example being able to clearly differentiate agitated and calm mental states.
Company research proposal was selected to be the semi-finalist at the US Advance Technology Program (ATP) managed by the National Institute of Standards and Technology. ATP Program funds high-risk high payoff path-breaking research from all technology areas. "We were very pleased and honored to be selected as semi-finalists in such a prestigious and tough competition", said Dr. Vladimir Polyshchuk, Biosignetics President and Technical Director. "Our research direction is now focused on early detection of silent heart diseases so that they can be treated using less invasive methods."
ABOUT BIOSIGNETICS
Biosignetics has developed and commercialized patent pending Heart Energy Signature format and method. Biosignetics is registered with FDA as equipment supplier. Company continues its research and regulatory efforts to prepare 510(K) FDA application for the clinical diagnosis software. Biosignetics is aggressively engaged in early detection research focusing on reliable detection of weak multi-component signals and patterns in otherwise noisy environment and is actively looking for clinical research partners in the medical community.
-------------------------------------------------
"Study: Most new doctors can't use stethoscope only 20 percent 'hear' common
heart problems", CNN Interactive, 1997, http://www.cnn.com/HEALTH/9709/02/nfm.heart.sounds/
# # #
If you'd like more information about this topic, or to schedule an interview, please call to Vladimir Kudriavtsev at 416-497-2356 or email to info@bsignetics.com
For More Information Contact:
Vladimir Kudriavtsev
VP Marketing and Technology
BioSignetics Corporation
29 Downing Ct, Exeter, NH 03833
Tel: 603 303-0708
FAX: 603 772-8706
Internet: info@bsignetics.com
This article courtesy of http://hearthealthysite.com.
You may freely reprint this article on your website or in
your newsletter provided this courtesy notice and the author
name and URL remain intact.
Submit
Your Article
|
|